ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that it is an Oak sponsor of the Cholangiocarcinoma Foundation Annual Conference 2018 in Salt Lake City, Utah.

The conference is organised by the Cholangiocarcinoma Foundation and will be held from 31 January to 2 February 2018. Bringing together researchers, healthcare professionals, policymakers, patients and their caregivers, the conference encourages the engagement of the medical and research communities on cholangiocarcinoma by providing a forum for knowledge and innovation exchange.

For more information, please refer to the English or Chinese press release.